

## Press Release

India



### *Sanofi India Limited (SIL) declares 8% growth in net sales for Q3-2024*

The Board of Sanofi India Limited (SIL) today approved its standalone and consolidated financial results, for Q3 and year to date ended on September 30<sup>th</sup>, 2024, after the demerger of its consumer healthcare business effective from June 1<sup>st</sup>, 2024.

Diabetes portfolio reported a high single digit growth with a good performance of Toujeo<sup>®</sup>, Lantus<sup>®</sup> and the successful launch of Soliqua<sup>®</sup> reinstating confidence and strength in our comprehensive diabetes portfolio.

The recently announced partnerships for CNS (Central Nervous System) and the CV (Cardiovascular) brands have established their foundation for acceleration and expansion in reach.

The Company delivered 6% growth in operating profit (\*). The Profit from Operations for Q3-2024 was at INR 110 crores versus INR 104 crores Q3-2023.

(\* ) Operating profit = Revenue from operations – Cost of goods sold and expenses

#### **Rodolfo Hrosz**

Managing Director, Sanofi India Limited

*“Fueled by our resolve to bring best-in-class and first-in-class innovative products to India, we successfully launched Soliqua<sup>®</sup> - our best-in-class diabetes drug for the premix segment. Soliqua is showing immense promise in significantly reducing the complexities of living with diabetes. Encouraged by positive patient outcomes, we already have the faith and confidence of thousands of doctors who continue to prescribe it. Our recently announced partnerships for Cardiovascular and CNS (Central Nervous System) categories have shown initial positive results, as our iconic established brands in these categories begin to expand their presence across the country. This momentum is significantly paving the way for our future plans, as we chase the miracles of science to improve people’s lives in India.”*

#### **Sanofi in India**

As Sanofi India, we are in a great place to make a difference. Present in the country for nearly seven decades, we have earned the trust of our customers and stakeholders for our commitment to promoting health. As we chase the miracles of science to improve people’s lives, we continue to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building.

Our India Charitable Access Program (InCAP) is the country’s longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. We conduct clinical trials here so that India can have quicker access to the latest from our global pipeline. Our worldclass manufacturing site in Goa produces for people in India and 60+ other countries. Sanofi has located one of its four global talent hubs in Hyderabad, India, from where wide range of services are provided globally.

Recognized by the ‘Top<sup>®</sup> Employers Institute’ – a global authority that honours excellence in people practices since 2019, our local entities include Sanofi India Limited (SIL - listed entity), Sanofi Healthcare India Pvt. Ltd. (SHIPL) and Sanofi Consumer Healthcare India Limited (SCHIL).

For more information, visit: [www.sanofi.in](http://www.sanofi.in) and [www.sanofiindialtd.com](http://www.sanofiindialtd.com), [LinkedIn](#) and [Twitter](#).

*Media Relations*

**Vinifer Gandhi** | [vinifer.gandhi@sanofi.com](mailto:vinifer.gandhi@sanofi.com)